These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31204237)

  • 1. SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia.
    Choi MY; Wang HY; Kipps TJ
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):321-325. PubMed ID: 31204237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
    Hallek M; Cheson BD; Catovsky D; Caligaris-Cappio F; Dighiero G; Döhner H; Hillmen P; Keating M; Montserrat E; Chiorazzi N; Stilgenbauer S; Rai KR; Byrd JC; Eichhorst B; O'Brien S; Robak T; Seymour JF; Kipps TJ
    Blood; 2018 Jun; 131(25):2745-2760. PubMed ID: 29540348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C
    Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
    Hallek M; Cheson BD; Catovsky D; Caligaris-Cappio F; Dighiero G; Döhner H; Hillmen P; Keating MJ; Montserrat E; Rai KR; Kipps TJ;
    Blood; 2008 Jun; 111(12):5446-56. PubMed ID: 18216293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of the 2018 iwCLL Guidelines update.
    O'Brien SM
    Clin Adv Hematol Oncol; 2018 Aug; 16 Suppl 15(8):1-16. PubMed ID: 30300339
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing minimal residual disease in chronic lymphocytic leukemia.
    Rawstron AC; Hillmen P
    Curr Hematol Malig Rep; 2008 Jan; 3(1):47-53. PubMed ID: 20425446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL).
    Eichhorst B; Hallek M
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):469-77. PubMed ID: 17707834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines.
    Molica S; Giannarelli D; Mirabelli R; Levato L; Gentile M; Lentini M; Morabito F
    Expert Rev Hematol; 2014 Oct; 7(5):691-5. PubMed ID: 25174547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of Chronic Lymphocytic Leukemia Using iwCLL 2018 Compared with NCI-WG96 Criteria in Cipto Mangunkusumo Hospital: A Practical Consideration in Resource Limited Setting.
    Sukrisman L; Rinaldi I
    Acta Med Indones; 2022 Oct; 54(4):531-539. PubMed ID: 36624709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dutch guidelines for the diagnosis and treatment of chronic lymphocytic leukaemia.
    Dutch/Belgium HOVON CLL working group
    Neth J Med; 2016 Feb; 74(2):68-74. PubMed ID: 26951351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
    Wierda WG; Rawstron A; Cymbalista F; Badoux X; Rossi D; Brown JR; Egle A; Abello V; Cervera Ceballos E; Herishanu Y; Mulligan SP; Niemann CU; Diong CP; Soysal T; Suzuki R; Tran HTT; Wu SJ; Owen C; Stilgenbauer S; Ghia P; Hillmen P
    Leukemia; 2021 Nov; 35(11):3059-3072. PubMed ID: 34168283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of minimal residual disease in chronic lymphocytic leukemia.
    Al-Sawaf O; Hallek M; Fischer K
    Clin Adv Hematol Oncol; 2022 Feb; 20(2):97-103. PubMed ID: 35120090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of chronic lymphocytic leukemia.
    Ghia P; Hallek M
    Haematologica; 2014 Jun; 99(6):965-72. PubMed ID: 24881042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting: commentary.
    O'Brien SM
    Clin Adv Hematol Oncol; 2018 Jan; 16 Suppl 2(1):16-19. PubMed ID: 29742092
    [No Abstract]   [Full Text] [Related]  

  • 17. [The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China （2015 edition）].
    Chinese Society of Hematology, Chinese Medical Association; Hematology Oncology Committee of China Anti-Cancer Association
    Zhonghua Xue Ye Xue Za Zhi; 2015 Oct; 36(10):809-13. PubMed ID: 26477756
    [No Abstract]   [Full Text] [Related]  

  • 18. Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.
    Tomuleasa C; Selicean C; Cismas S; Jurj A; Marian M; Dima D; Pasca S; Petrushev B; Moisoiu V; Micu WT; Vischer A; Arifeen K; Selicean S; Zdrenghea M; Bumbea H; Tanase A; Grewal R; Pop L; Aanei C; Berindan-Neagoe I
    Crit Rev Clin Lab Sci; 2018 Aug; 55(5):329-345. PubMed ID: 29801428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?
    Böttcher S; Hallek M; Ritgen M; Kneba M
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):267-88. PubMed ID: 23561473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission.
    Shadman M; Gopal AK; Kammerer B; Becker PS; Maloney DG; Pender B; Shustov AR; Press OW; Pagel JM
    Leuk Lymphoma; 2016; 57(3):572-6. PubMed ID: 26133724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.